HIGH TIDE INC (HITI.CA) Stock Fundamental Analysis
Canada - TSX-V:HITI - CA42981E4013 - Common Stock
5.04 CAD
-0.03 (-0.59%)
HITI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. While HITI seems to be doing ok healthwise, there are quite some concerns on its profitability. HITI is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year HITI has reported negative net income.
HITI had a positive operating cash flow in the past year.
In the past 5 years HITI always reported negative net income.
HITI had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
With a Return On Assets value of -3.76%, HITI perfoms like the industry average, outperforming 50.00% of the companies in the same industry.
HITI has a Return On Equity of -6.93%. This is comparable to the rest of the industry: HITI outperforms 58.82% of its industry peers.
HITI has a better Return On Invested Capital (4.61%) than 82.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROIC | 4.61% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of HITI (2.30%) is better than 70.59% of its industry peers.
The Gross Margin of HITI (25.83%) is worse than 67.65% of its industry peers.
HITI's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), HITI is destroying value.
The number of shares outstanding for HITI has been increased compared to 1 year ago.
HITI has more shares outstanding than it did 5 years ago.
HITI has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 3.66 indicates that HITI is not in any danger for bankruptcy at the moment.
The Altman-Z score of HITI (3.66) is better than 91.18% of its industry peers.
HITI has a debt to FCF ratio of 4.08. This is a neutral value as HITI would need 4.08 years to pay back of all of its debts.
HITI has a better Debt to FCF ratio (4.08) than 85.29% of its industry peers.
HITI has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
HITI has a Debt to Equity ratio of 0.43. This is comparable to the rest of the industry: HITI outperforms 44.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Altman-Z | 3.66 |
ROIC/WACC0.52
WACC8.92%
2.3 Liquidity
HITI has a Current Ratio of 1.85. This is a normal value and indicates that HITI is financially healthy and should not expect problems in meeting its short term obligations.
HITI's Current ratio of 1.85 is in line compared to the rest of the industry. HITI outperforms 55.88% of its industry peers.
A Quick Ratio of 1.29 indicates that HITI should not have too much problems paying its short term obligations.
HITI's Quick ratio of 1.29 is in line compared to the rest of the industry. HITI outperforms 50.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 |
3. Growth
3.1 Past
The earnings per share for HITI have decreased strongly by -321.45% in the last year.
HITI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 11.18%.
HITI shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 75.59% yearly.
EPS 1Y (TTM)-321.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.71%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.9%
3.2 Future
The Earnings Per Share is expected to grow by 74.44% on average over the next years. This is a very strong growth
Based on estimates for the next years, HITI will show a quite strong growth in Revenue. The Revenue will grow by 14.96% on average per year.
EPS Next Y-12.22%
EPS Next 2Y104.72%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue Next Year11.85%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y14.96%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for HITI. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 36.51, HITI can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of HITI indicates a somewhat cheap valuation: HITI is cheaper than 76.47% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.29, HITI is valued quite expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, HITI is valued a bit cheaper than the industry average as 70.59% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HITI indicates a somewhat cheap valuation: HITI is cheaper than 76.47% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.28 | ||
| EV/EBITDA | 12.58 |
4.3 Compensation for Growth
HITI's earnings are expected to grow with 96.71% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.72%
EPS Next 3Y96.71%
5. Dividend
5.1 Amount
No dividends for HITI!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX-V:HITI (10/2/2025, 7:00:00 PM)
5.04
-0.03 (-0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners6.97%
Inst Owner ChangeN/A
Ins Owners8.32%
Ins Owner ChangeN/A
Market Cap438.88M
Analysts80
Price Target7.91 (56.94%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)250.72%
Min EPS beat(2)-8%
Max EPS beat(2)509.45%
EPS beat(4)1
Avg EPS beat(4)43.58%
Min EPS beat(4)-315.76%
Max EPS beat(4)509.45%
EPS beat(8)5
Avg EPS beat(8)89.17%
EPS beat(12)9
Avg EPS beat(12)71.28%
EPS beat(16)12
Avg EPS beat(16)52.88%
Revenue beat(2)1
Avg Revenue beat(2)-0.1%
Min Revenue beat(2)-1.49%
Max Revenue beat(2)1.3%
Revenue beat(4)3
Avg Revenue beat(4)0.64%
Min Revenue beat(4)-1.49%
Max Revenue beat(4)1.6%
Revenue beat(8)5
Avg Revenue beat(8)0.05%
Revenue beat(12)9
Avg Revenue beat(12)1.51%
Revenue beat(16)13
Avg Revenue beat(16)7.42%
PT rev (1m)0%
PT rev (3m)10.71%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-4.99%
EPS NY rev (3m)-27.27%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-3.71%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)-0.13%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.51 | ||
| P/S | 0.77 | ||
| P/FCF | 22.28 | ||
| P/OCF | 15.01 | ||
| P/B | 3.1 | ||
| P/tB | 8.45 | ||
| EV/EBITDA | 12.58 |
EPS(TTM)-0.13
EYN/A
EPS(NY)0.14
Fwd EY2.74%
FCF(TTM)0.23
FCFY4.49%
OCF(TTM)0.34
OCFY6.66%
SpS6.53
BVpS1.62
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.76% | ||
| ROE | -6.93% | ||
| ROCE | 6.4% | ||
| ROIC | 4.61% | ||
| ROICexc | 6.71% | ||
| ROICexgc | 18.48% | ||
| OM | 2.3% | ||
| PM (TTM) | N/A | ||
| GM | 25.83% | ||
| FCFM | 3.47% |
ROA(3y)-14.91%
ROA(5y)-13.84%
ROE(3y)-26.27%
ROE(5y)-34.31%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.25%
GM growth 5Y-5.48%
F-Score5
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.43 | ||
| Debt/FCF | 4.08 | ||
| Debt/EBITDA | 1.67 | ||
| Cap/Depr | 41.17% | ||
| Cap/Sales | 1.68% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 80.65% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.85 | ||
| Quick Ratio | 1.29 | ||
| Altman-Z | 3.66 |
F-Score5
WACC8.92%
ROIC/WACC0.52
Cap/Depr(3y)28.99%
Cap/Depr(5y)34.63%
Cap/Sales(3y)1.88%
Cap/Sales(5y)2.98%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-321.45%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.71%
EPS Next Y-12.22%
EPS Next 2Y104.72%
EPS Next 3Y96.71%
EPS Next 5Y74.44%
Revenue 1Y (TTM)11.18%
Revenue growth 3Y42.34%
Revenue growth 5Y75.59%
Sales Q2Q%13.9%
Revenue Next Year11.85%
Revenue Next 2Y16.73%
Revenue Next 3Y17.75%
Revenue Next 5Y14.96%
EBIT growth 1Y2.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year418.19%
EBIT Next 3Y133.23%
EBIT Next 5Y77.23%
FCF growth 1Y38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.53%
OCF growth 3YN/A
OCF growth 5YN/A